8 results about "Verapamil" patented technology

The invention discloses a preparation method of an effective part of anchusa edulis, which comprises the following steps: (1) carrying out heating reflux extraction on anchusa edulis, and concentrating an extracting solution to obtain an anchusa edulis concentrated solution; and (2) adsorbing and eluting the concentrated solution of the anchusa through macroporous resin and / or polyamide resin to obtain the first effective part of the anchusa and / or the second effective part of the anchusa. The first effective part and / or the second effective part of the anchusa can recover human myocardial cell injury caused by verapamil, wherein the first effective part of the anchusa has the strongest activity in the aspects of promoting the overall activity of human myocardial cells, inhibiting the death of the human myocardial cells and promoting the proliferation of the human myocardial cells.

The invention discloses a pyrimido triazole derivative, the pyrimido triazole derivative is a pyrimido triazole derivative containing amino dithio ester, and the pyrimido triazole derivative has the following general formula I: # imgabs0 #. The reversion activity of the pyrimido triazole derivative containing amino dithio ester disclosed by the invention is obviously superior to that of an ABCB1 inhibitor Verapamil, and the reversion activity of the pyrimido triazole derivative containing amino dithio ester is obviously superior to that of the ABCB1 inhibitor Verapamil; the compound can be used as a candidate or lead compound for further development and is applied to preparation of a drug resistance reversal agent.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

This invention belongs to the field of biomedical technology, specifically relating to a composition for treating ischemic heart disease and its application. This invention combines two or more of ginsenoside Rg1, ginsenoside Rb1, ginsenoside Re, and notoginsenoside R1, which can significantly downregulate the levels of myocardial enzymes, aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) in myocardial coronary effusion, with an inhibitory effect significantly higher than that of a single saponin component and the positive control drug verapamil. Simultaneously, the composition exhibits better recovery capabilities for coronary flow (CF), left ventricular developmental pressure (LVDP), maximum rate of decrease in left ventricular pressure (-dp / dtmax), and heart rate (HR) in myocardial coronary effusion. Therefore, the composition can alleviate and treat myocardial ischemia-reperfusion injury through multiple targets and mechanisms, fundamentally inhibiting the development of ischemic heart disease.

The invention discloses a method for detecting colopivir in plasma by an HPLC-MS / MS (high performance liquid chromatography-mass spectrometry / mass spectrometry) method. According to the method, a protein precipitation method is adopted for pretreatment, a Waters CORTECS C8 chromatographic column is adopted as a chromatographic condition, a water solution containing 0.01% formic acid of 2 mM ammonium acetate and acetonitrile are taken as mobile phases, and gradient elution is carried out; an electrospray ionization source (ESI) tandem mass spectrum is adopted as a mass spectrum condition, and verapamil is used as an internal standard for quantitative detection. The method disclosed by the invention is simple and convenient to operate, high in analysis speed, high in sensitivity and suitable in linear range, and meets pre-clinical and clinical research large-batch sample analysis requirements.

The application discloses a method for detecting calopivir in blood plasma by HPLC-MS / MS. The method is pretreated by a protein precipitation method, and chromatographic conditions are as follows: a Waters CORTECS C8 chromatographic column is used, 2 mM ammonium acetate containing 0.01% formic acid in water and acetonitrile are used as mobile phases, and gradient elution is carried out; mass spectrometry conditions are as follows: an electrospray ionization source (ESI) tandem mass spectrometer is used, and verapamil is used as an internal standard for quantitative detection. The method is simple in operation, fast in analysis speed, high in sensitivity, suitable in linear range, and meets the requirements of large quantities of sample analysis in preclinical and clinical research.

The invention provides an application of verapamil in preparation of a medicine for treating Rett syndrome. The invention discloses the treatment effect of verapamil on the Rett syndrome for the first time, and verifies the treatment mechanism and effect of verapamil: the verapamil can inhibit astrocyte activation and reduce the expression of inflammatory factors IL-1beta and TNF-alpha by remarkably improving the expression level of postsynaptic density protein PSD95, increases the number of myelination axons, and improves the treatment effect of the verapamil on the Rett syndrome. The improvement of dyskinesia, the recovery of social behavior defects and the prolonging of lifetime are cooperatively realized. On the basis of existing clinical safety data of verapamil, the development risk of new indications is remarkably reduced; and the requirements of different clinical scenes are met through the design of various dosage forms.

The invention discloses an inclusion compound, a composition and a medicinal preparation containing the inclusion compound, and a method for preparing the inclusion compound, the composition or the medicinal preparation. Specifically, the clathrate compound contains vilazodone or a pharmaceutically acceptable salt and a clathrate material of vilazodone.